Skip to content
★ Sign in to follow
인피

인피니트헬스케어 Stock: price and insider trades · South Korea

KR·Mcap ₩271.6BHealth Care

No insider purchase over the last 90 days. The latest, by 솔본, was filed 31 Mar 2026.

인피니트헬스케어: what insiders have been doing

Every trade that managers of 인피니트헬스케어 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. In the past year (2 November 2025 to 2 November 2026), 6 filings came from 5 insiders.

Only purchases show up on the open market, 2 purchases in all, filed by 2 insiders. The totals exclude 2 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 board member.

The last insider purchase was made public on 31 March 2026, 224 days ago.

With 6 filings in twelve months, the company is quieter than the median of 7 filings across the 2,655 companies we follow on the same exchange. Our records for 인피니트헬스케어 go back to 2021, with 9 purchases and no sales on the open market in total.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
24
Thresholds
n/a
Buy Volume
€5M
9 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
솔본4 buys
김대은1 buy

Since the insiders bought

  • Filed 31 Mar 2026 · 224 days ago · €89k
    +78.2%
    Entry ₩6,250 · Close 30 Oct 2026 ₩11,140

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 936 of 26,911 companies
81.2
score / 100
Value
74
Quality
88
FCF yld4.9%
Earn yld9.7%
EV/EBITDA7.3x
ROE·
Gross mgn61%
Net mgn26%
Debt/EBITDA0.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩11,140
Analyst consensus
·
Income statement
Revenue₩102.4B
Gross profit₩63B61% margin
EBITDA₩37.8B37% margin
Net income₩26.4B25.8% margin
Balance sheet & cash
Market cap₩271.6B
Total debt₩2.5B
Free Cash Flow₩13.3B
Last declaration on 8 July 2026
Declarations28 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ●
    대량보유자Executives(filed)
    0DART
    KRXDART:20260708000048
  • ▲
    -Executives
    €89kest.0DART
    24,400 sharesShareKRXDART:20260331003848
    Canonical exit: 23 Jun 2026 (T+90)
  • ▲
    이사Executives(filed)
    €34est.0DART
    10 sharesShareKRXDART:20260116000434
    Canonical exit: 16 Apr 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    10%이상주주Executives(filed)
    €200kest.0DART
    51,611 sharesShareKRXDART:20250825000266
    Canonical exit: 23 Nov 2025 (T+90)
  • ▲
    대량보유자Executives
    €1.7Mest.0DART
    378,465 sharesKRXDART:20250804000162
    Canonical exit: 26 Oct 2025 (T+90)
  • ▲
    10%이상주주Executives(filed)
    €1.7Mest.0DART
    378,465 sharesShareKRXDART:20250804000156
    Canonical exit: 2 Nov 2025 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    -Executives(filed)
    €127kest.0DART
    44,163 sharesShareKRXDART:20241025000111
    Canonical exit: 23 Jan 2025 (T+90)

25 of 28 declarations

About 인피니트헬스케어

Infinite Healthcare is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing technological solutions to enhance healthcare services.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations